Van beleggers
voor beleggers
desktop iconMarkt Monitor

Ontvang nu dagelijks onze kooptips!

word abonnee

OTC fonds RDGL

4 Posts
| Omlaag ↓
  1. kar.b 18 oktober 2018 19:37
    Het aandeel met de meeste potentie is RDGL

    Het staat genoteerd aan de Amerikaanse OTC
    De koers is nu ongeveer 0,014 dollar
    Zij presenteren binnenkort een product dat bepaalde vormen van kanker behandeld. Potentie is hier oneindig groot...

    The strategic market sector of Vivos Inc. is therapeutic isotope applications. Currently, the Company is engaged in the development of RadioGel™, a Yttrium-90 based brachytherapy device, for the treatment of tumors. Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside the treatment area.

    The company is engaging the FDA for permission to use RadioGel™ for the treatment of advanced basal and squamous cell skin cancers. The RadioGel™ Veterinary Solutions division of Vivos is focused on demonstrating the safety and therapeutic effectiveness for different animal cancers in four different university veterinary hospitals. Vivos is positioning itself so that after this demonstration phase, The Company can begin to generate revenues through the sale of RadioGel™ to private animal clinics.

    The Company currently is outsourcing material aspects of manufacturing of its product in the United States and intends to enter into licensing arrangements outside of the United States for the manufacturing and distribution of RadioGel™ in other countries.

    What is RadioGel™?

    RadioGel™ is a hydrogel liquid containing tiny Yttrium-90 phosphate particles to be injected into a tumor. This hydrogel is a liquid at temperatures below body temperature but begins to gel, harden, upon injection as the temperature increases to normal body temperature, thereby locking the particles in place. The particles emit a very high concentrated and contained beta irradiation to kill the tumor. The beta radiation has a short penetration distance so there is minimal collateral damage to healthy tissues outside of the injected area.
    RadioGel™ also has a short half-life – delivering more than 90% of its therapeutic radiation within 10 days. This compares favorably to other available treatment options requiring up to 6 weeks or more to deliver a full course of radiation therapy. This is an outpatient treatment much safer to the personnel treating the patient than competing brands and the patient can go home immediately with no risk to family members.
4 Posts
|Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum


AEX 856,84 +0,32%
EUR/USD 1,0853 +0,13%
FTSE 100 7.642,17 -0,52%
Germany40^ 17.697,60 -0,21%
Gold spot 2.099,59 +0,81%
NY-Nasdaq Composite 16.274,94 +1,14%


AMG Cr...



Nieuws Forum Meer»

Column Forum Meer»

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links